In vitro anti-cancer activity of chamaejasmenin B and neochamaejasmin C isolated from the root of Stellera chamaejasme L

Abstract

Aim: To examine the anti-cancer effects of chamaejasmenin B and neochamaejasmin C, two biflavonones isolated from the root of Stellera chamaejasme L (known as the traditional Chinese herb Rui Xiang Lang Du) in vitro. Methods: Human liver carcinoma cell lines (HepG2 and SMMC-7721), a human non-small cell lung cancer cell line (A549), human osteosarcoma cell lines (MG63, U2OS, and KHOS), a human colon cancer cell line (HCT-116) and a human cervical cancer cell line (HeLa) were used. The anti-proliferative effects of the compounds were measured using SRB cytotoxicity assay. DNA damage was detected by immunofluorescence and Western blotting. Apoptosis and cell cycle distribution were assessed using flow cytometry analysis. The expression of the related proteins was examined with Western blotting analysis. Results: Both chamaejasmenin B and neochamaejasmin C exerted potent anti-proliferative effects in the 8 human solid tumor cell lines. Chamaejasmenin B (the IC 50 values ranged from 1.08 to 10.8 μmol/L) was slightly more potent than neochamaejasmin C (the IC 50 values ranged from 3.07 to 15.97 μmol/L). In the most sensitive A549 and KHOS cells, the mechanisms underlying the anti-proliferative effects were characterized. The two compounds induced prominent expression of the DNA damage marker γ-H2AX as well as apoptosis. Furthermore, treatment of the cells with the two compounds caused prominent G 0 /G 1 phase arrest. Conclusion: Chamaejasmenin B and neochamaejasmin C are potential anti-proliferative agents in 8 human solid tumor cell lines in vitro via inducing cell cycle arrest, apoptosis and DNA damage.

A New Dicoumarinyl Ether from the Roots of Stellera chamaejasme L

“…Previous phytochemical studies of S. chamaejasme showed the presence of groups of biflavonoids, diterpenes, lignans, and coumarins [3][4][5][6][7][8][9][10][11][12]. In our continuous studies on the chemical constituents of S. chamaejasme, a new bicoumarin, 3-hydroxy-6-methoxy-7,7'-dicoumarinyl ether (1, Figure 1) was isolated, together with the known coumarin umbelliferone (2). Here, we report the isolation and structure elucidation of the new compound.…”

“…The EtOAc fraction (160 g) was subjected to column chromatography (CC) with a PE/EtOAc gradient system of increasing polarity (9:1, 8:2, 7:3, 6:4, 5:5) as eluent to give six fractions (Fr. [1][2][3][4][5][6] …”

“…Stellera chamaejasme L. (Ruixianglangdu in Chinese, family Thymelaeaceae), has been used in China as an important traditional medicine for the treatment of scabies, tinea, stubborn skin ulcers, chronic tracheitis, cancer, and tuberculosis [1,2]. Previous phytochemical studies of S. chamaejasme showed the presence of groups of biflavonoids, diterpenes, lignans, and coumarins [3][4][5][6][7][8][9][10][11][12].…”

Strategy for chemotherapeutic delivery using a nanosized porous metal-organic framework with a central composite design

“…Since its establishment, it has become an important cell line for screening and studying the pathogenesis of liver cancer. [54][55][56][57] The MTT assay demonstrated the cytotoxicity of the 5-FUloaded nanoHKUST-1. NanoHKUST-1 at low concentration (15 µg/mL) showed slight inhibition (24.3%), which was the same as that of the 5-FU-solution (10.2%).…”

Biotoxins for Cancer Therapy

“…The two compounds are potential anti-proliferative agents in 8 human solid tumor cell lines: Human liver carcinoma cell lines (HepG2 and SMMC-7721), a human non-small cell lung cancer cell line (A549), human osteosarcoma cell lines (MG63, U2OS, and KHOS), a human colon cancer cell line (HCT-116) and a human cervical cancer cell line (HeLa). Furthermore, they induce cell cycle arrest, apoptosis and DNA damage (Zhang et al, 2013). In addition, persin, previously identified from avocado leaves as the toxic principle responsible, induces Bim-dependent apoptosis in human breast cancer cells, and could represent a novel class of microtubule-targeting agent with potential specificity for breast cancers (Butt et al, 2006).…”